In a related editorial, the authors are enthusiastic about the finding, highlighting that the potential role for aspirin (especially considering affordability) to be used as chemoprevention for hepatocellular carcinoma would be relevant to patients worldwide. However, a recommendation for widespread use of aspirin across the HBV population is premature, as important questions remain, including duration of therapy, age at initiation, degree of benefit for patients taking nucleos(t)ide analogues, and risk for gastroduodenal toxic effects.